Guggenheim Capital LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $740,980 - $813,062	19,019 Added 73.64%	44,847 $1.83 Million
Q1 2024 May 14, 2024	BUY	$40.88 - $43.27 $50,241 - $53,178	1,229 Added 5.0%	25,828 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $206,287 - $431,911	10,177 Added 70.57%	24,599 $1.04 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $21,374 - $33,665	1,055 Added 7.89%	14,422 $314,000
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $34,487 - $51,053	1,443 Added 12.1%	13,367 $424,000
Q1 2023 May 10, 2023	BUY	$22.82 - $35.32 $32,632 - $50,507	1,430 Added 13.63%	11,924 $290,000
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $266,022 - $335,388	10,494 New	10,494 $330,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.